Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of DirectorsPRNewsWire • 12/27/21
BiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary SharesPRNewsWire • 12/27/21
BiondVax Announces Proposed Underwritten Public Offering of American Depositary SharesPRNewsWire • 12/24/21
BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, GermanyPRNewsWire • 12/22/21
BiondVax announces Third Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 11/30/21
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business UpdatePRNewsWire • 11/24/21
BiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodiesPRNewsWire • 10/19/21
BiondVax Announces Second Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 08/26/21
BiondVax Announces First Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 06/23/21
BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdatePRNewsWire • 05/13/21
BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on OfferingPRNewsWire • 02/10/21
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary SharesPRNewsWire • 01/29/21
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary SharesPRNewsWire • 01/28/21
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine CandidatePRNewsWire • 10/23/20